About
David Hallal is the Board Chairman of Kalaris Therapeutics David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman and CEO of AlloVir, an ElevateBio portfolio company. Previously, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate, Ultomiris, from a preclinical stage to registration trials in mult
Position in the VCSift Database
- • 3 investors at ElevateBio are tracked.
- • 288 investors hold the CEO, Chair, & Co-Founder role in VCSift. David Hallal is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like David
Search Investors